Nitrendipine and ACE inhibitors

A. Zanchetti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous. First, dihydropyridines cause a variable amount of reflex sympathetic activation, whereas ACE inhibitors blunt sympathetic activity at different central and peripheral levels. Second, dihydropyridines produce an almost exclusive arteriolar dilatation, and a more balanced arteriolar and venous dilatation might result from their association with an ACE inhibitor. Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition. More limited information is available on the doses of calcium antagonist and ACE inhibitor that are best suited for combined therapy. Careful studies should be performed to compare the dose-response curves of either agent to be combined and of possible dose combinations, particularly if combinations of agents of the two classes are planned in the same tablet.

Original languageEnglish
JournalJournal of Cardiovascular Pharmacology
Volume12
Issue numberSUPPL. 4
Publication statusPublished - 1988

Fingerprint

Nitrendipine
Dihydropyridines
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Dilatation
Calcium
Peptidyl-Dipeptidase A
Renin
Antihypertensive Agents
Tablets
Reflex

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Nitrendipine and ACE inhibitors. / Zanchetti, A.

In: Journal of Cardiovascular Pharmacology, Vol. 12, No. SUPPL. 4, 1988.

Research output: Contribution to journalArticle

Zanchetti, A 1988, 'Nitrendipine and ACE inhibitors', Journal of Cardiovascular Pharmacology, vol. 12, no. SUPPL. 4.
Zanchetti, A. / Nitrendipine and ACE inhibitors. In: Journal of Cardiovascular Pharmacology. 1988 ; Vol. 12, No. SUPPL. 4.
@article{cad218a6b3ec49c095d7d3b5bf09519b,
title = "Nitrendipine and ACE inhibitors",
abstract = "There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous. First, dihydropyridines cause a variable amount of reflex sympathetic activation, whereas ACE inhibitors blunt sympathetic activity at different central and peripheral levels. Second, dihydropyridines produce an almost exclusive arteriolar dilatation, and a more balanced arteriolar and venous dilatation might result from their association with an ACE inhibitor. Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition. More limited information is available on the doses of calcium antagonist and ACE inhibitor that are best suited for combined therapy. Careful studies should be performed to compare the dose-response curves of either agent to be combined and of possible dose combinations, particularly if combinations of agents of the two classes are planned in the same tablet.",
author = "A. Zanchetti",
year = "1988",
language = "English",
volume = "12",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Nitrendipine and ACE inhibitors

AU - Zanchetti, A.

PY - 1988

Y1 - 1988

N2 - There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous. First, dihydropyridines cause a variable amount of reflex sympathetic activation, whereas ACE inhibitors blunt sympathetic activity at different central and peripheral levels. Second, dihydropyridines produce an almost exclusive arteriolar dilatation, and a more balanced arteriolar and venous dilatation might result from their association with an ACE inhibitor. Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition. More limited information is available on the doses of calcium antagonist and ACE inhibitor that are best suited for combined therapy. Careful studies should be performed to compare the dose-response curves of either agent to be combined and of possible dose combinations, particularly if combinations of agents of the two classes are planned in the same tablet.

AB - There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous. First, dihydropyridines cause a variable amount of reflex sympathetic activation, whereas ACE inhibitors blunt sympathetic activity at different central and peripheral levels. Second, dihydropyridines produce an almost exclusive arteriolar dilatation, and a more balanced arteriolar and venous dilatation might result from their association with an ACE inhibitor. Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition. More limited information is available on the doses of calcium antagonist and ACE inhibitor that are best suited for combined therapy. Careful studies should be performed to compare the dose-response curves of either agent to be combined and of possible dose combinations, particularly if combinations of agents of the two classes are planned in the same tablet.

UR - http://www.scopus.com/inward/record.url?scp=0024234782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024234782&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 4

ER -